Utah’s AI Office, Medical Board, FSMB Converse With FDA Amid AI Prescribing Squabble

The Utah medical board, a key medical board stakeholder group and Utah’s artificial intelligence office are in conversations with FDA as they navigate next steps on the state’s controversial AI prescribing pilot, hoping to lay the groundwork for artificial intelligence policies that could be adopted in other states as the technologies work their way into states’ infrastructures.

Vega Health CEO Mark Sendak, who testified in front of the board, was quoted in the story. He said, “AI in healthcare is not a static product that can be approved once and left alone. It is a dynamic system that can drift, degrade, and produce unexpected outputs as patient populations shift , workflows change, and the underlying data systems evolve. This means that the right model for oversight is not pre-market approval, but post-implementation continuous monitoring.”

“This isn’t a question about whether AI should be regulated at the state or federal level. Efforts like the AI regulatory sandbox in Utah are highly innovative and valuable because they fill these gaps.”